23andMe is still the strongest mainstream buy when you want ancestry and health reporting in one account. The $99 entry tier covers ancestry only, but the real value case starts at the $199 Premium tier, where FDA-authorized health reports, carrier status, and pharmacogenetics come in.
Skip it if your main goal is genealogy. For relatives, records, and family-tree work, AncestryDNA is the stronger starting point. This review covers who should buy 23andMe, what you actually get, and where the money goes.
Key Takeaways
Here is the short version before the full review:
- 23andMe is worth buying for health plus ancestry. It is not the best first choice for genealogy-focused work.
- The entry price is $99 for the Ancestry Service tier. Premium is $199 and unlocks the health dashboard.
- Health reports are FDA-authorized and cover carrier status for 40+ conditions, health predispositions, and pharmacogenetics across 55+ reports.
- Ancestry tools are solid but not category-leading. You get 4,500+ regions, DNA relatives, haplogroups, and family-tree features.
- The 2025 ownership change matters. TTAM Research Institute completed the acquisition on July 14, 2025. The service continues to operate.
Our Verdict
23andMe still makes the most sense when you want one account that combines ancestry, carrier status, pharmacogenetics, and health screening. No other mainstream consumer DNA brand packages all of those together with FDA authorization across 55+ reports.
The product does not try to be the deepest genealogy tool. If your main question is about relatives and records, AncestryDNA is the better starting point. But if health information is part of why you are buying, 23andMe earns its price.
What You Get
23andMe solves a different job from ancestry-first platforms. The ancestry side is polished, but the reason to choose this brand is that health reporting lives in the same account.
Ancestry Reports
You get ancestry breakdowns across 4,500+ regions, DNA relatives, family-tree tools, haplogroups, and historical matches. The geographic detail is strong for casual exploration. It does not feed into a records-based workflow the way AncestryDNA does, but for buyers who are here for health-plus-ancestry, the ancestry side holds up.
Health Dashboard
This is where 23andMe separates from the field. Premium unlocks genetic health screening, carrier status for 40+ conditions including cystic fibrosis and sickle cell anemia, and pharmacogenetic reports. These reports are FDA-authorized — a distinction no other mainstream consumer DNA kit matches at this price point.
Total Health ($499) adds exome sequencing, biannual blood testing, and clinician-guided care. That tier targets buyers who want genetics-informed clinical support, not just a consumer dashboard.
Privacy Controls
You can download your raw data, manage research consent, request account deletion, and discard your physical sample. Two-step verification is required for all accounts. These controls matter more than usual given the 2025 ownership transition.
Who It Is Best For
If you are planning a family and want carrier-status screening before that conversation with a clinician, 23andMe gives you a starting point in one purchase. The carrier reports cover over 40 conditions and are designed as screening tools — not replacements for clinical genetic testing.
If you want a single genetics dashboard that covers ancestry, health predispositions, and pharmacogenetics without managing multiple services, this is the most practical mainstream option. Start with Premium if health is part of the goal.
Skip 23andMe if your real priority is building a family tree, finding more relatives, or working with historical records over time. That job belongs to AncestryDNA. Also skip it if you expect a consumer DNA test to act like a medical diagnosis — the reports are screening tools, and the company says they should not replace clinical evaluation.
Pricing, Privacy, and Important Caveats
As of March 2026, the lineup has three tiers. The $99 Ancestry Service is the entry point for ancestry-only buyers. Premium at $199 is the real decision point — that is where health reporting justifies choosing 23andMe over an ancestry-first kit. Total Health at $499 adds clinical-grade features and renews at $199 per year.
Renewal costs deserve attention. Premium renews at $69 per year. If you do not plan to use the health dashboard long term, factor that into the purchase decision.
On platform trust: 23andMe filed Chapter 11 on March 23, 2025. TTAM Research Institute completed the acquisition of its assets on July 14, 2025. The consumer service still operates, and privacy controls remain in place. Review the current privacy policy before buying if platform continuity ranks high for you.
The most important medical caveat: health reports are screening tools, not diagnoses. If a result affects a medical decision, talk to a genetic counselor or qualified clinician before acting on it.
The Bottom Line
We recommend 23andMe if you want ancestry and health in one product — that is the question worth getting right before you spend. If your real goal is family history, start with AncestryDNA instead. If you want a broader health-focused shortlist, read the best DNA tests for health next.
